ReNeuron Group Plc (LON:RENE) expects first results in December from the current dosing trial of its flagship stem cell product CTX.
All patients have now been treated in the Phase II clinical study, which is aimed at sufferers of motor disability as a result of an ischaemic stroke.
The three month follow-up data will be a “key clinical milestone” said the group.
If successful, application for a Phase II/III controlled efficacy trial for CTX will be filed early in 2017.
"Our therapeutic development programmes remain on track with the next key clinical milestone being Phase II data from the PISCES II study in disabled stroke patients, due in December of this year,” said chief executive officer Olav Hellebø.
Elsewhere, its CTX cell therapy candidate for critical limb ischaemia (CLI) is currently in a Phase I clinical trial in the UK.
CLI is a condition that results in loss of blood flow to the lower limb that can lead to amputation, common in diabetics.
“ReNeuron remains well-funded to advance all of its therapeutic programmes through to further significant clinical milestones and we look forward to reporting further progress in the months ahead,” added Hellebø.